SEC Tracker
Get the app

Tvardi Therapeutics TVRD

Tvardi Therapeutics (TVRD) filed its Q3 2025 quarterly report (Form 10-Q), providing investors with an update on the company's financial performance and operational activities during the period. The filing highlights the company's progress on key drug development programs and financial position, which is crucial information for tracking Tvardi's short-term performance and assessing its long-term growth prospects.

Form
10-Q
Filed
Importance
Notable

Open in the appGet the appView on EDGAR

Get an email when Tvardi Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Silence Therapeutics SLN public float $206M, Jun 30, 2025
  2. Cardiff Oncology CRDF public float $205M, Jun 30, 2025
  3. Rezolute RZLT public float $204M, Dec 31, 2025
  4. Natures Sunshine Products NATR public float $211M, Jun 30, 2025
  5. Rocket Pharmaceuticals RCKT public float $213M, Jun 30, 2025